Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.14 USD
−78.31 M USD
0.00 USD
17.41 M
About Rapport Therapeutics, Inc.
Sector
Industry
CEO
Abraham N. Ceesay
Website
Headquarters
Boston
Founded
2022
FIGI
BBG01FRNQ4P1
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of RAPP is 10.05 USD — it has increased by 5.14% in the past 24 hours. Watch Rapport Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Rapport Therapeutics, Inc. stocks are traded under the ticker RAPP.
RAPP stock has fallen by −1.64% compared to the previous week, the month change is a −22.63% fall, over the last year Rapport Therapeutics, Inc. has showed a −44.17% decrease.
We've gathered analysts' opinions on Rapport Therapeutics, Inc. future price: according to them, RAPP price has a max estimate of 42.00 USD and a min estimate of 35.00 USD. Watch RAPP chart and read a more detailed Rapport Therapeutics, Inc. stock forecast: see what analysts think of Rapport Therapeutics, Inc. and suggest that you do with its stocks.
RAPP reached its all-time high on Oct 16, 2024 with the price of 29.74 USD, and its all-time low was 6.43 USD and was reached on Mar 4, 2025. View more price dynamics on RAPP chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RAPP stock is 9.99% volatile and has beta coefficient of 2.17. Track Rapport Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Rapport Therapeutics, Inc. there?
Today Rapport Therapeutics, Inc. has the market capitalization of 372.99 M, it has decreased by −2.40% over the last week.
Yes, you can track Rapport Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Rapport Therapeutics, Inc. is going to release the next earnings report on May 28, 2025. Keep track of upcoming events with our Earnings Calendar.
RAPP earnings for the last quarter are −0.57 USD per share, whereas the estimation was −0.64 USD resulting in a 10.99% surprise. The estimated earnings for the next quarter are −0.76 USD per share. See more details about Rapport Therapeutics, Inc. earnings.
Rapport Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
RAPP net income for the last quarter is −19.98 M USD, while the quarter before that showed −17.54 M USD of net income which accounts for −13.93% change. Track more Rapport Therapeutics, Inc. financial stats to get the full picture.
No, RAPP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 25, 2025, the company has 69.00 employees. See our rating of the largest employees — is Rapport Therapeutics, Inc. on this list?
Like other stocks, RAPP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Rapport Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Rapport Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Rapport Therapeutics, Inc. stock shows the strong sell signal. See more of Rapport Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.